LivaNova (NASDAQ:LIVN) updated its FY 2021 earnings guidance on Monday. The company provided EPS guidance of $1.750-$2.050 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.770. The company issued revenue guidance of -.
A number of brokerages have commented on LIVN. Piper Sandler reduced their price objective on LivaNova from $99.00 to $98.00 and set an overweight rating on the stock in a research note on Tuesday, June 1st. Zacks Investment Research upgraded LivaNova from a sell rating to a hold rating in a research note on Wednesday, August 4th. Robert W. Baird boosted their price objective on LivaNova from $100.00 to $105.00 and gave the stock an outperform rating in a research note on Tuesday, August 17th. They noted that the move was a valuation call. Finally, Needham & Company LLC lifted their target price on LivaNova from $104.00 to $117.00 and gave the stock a buy rating in a research report on Friday, August 20th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of Buy and an average price target of $101.00.
Shares of NASDAQ LIVN traded up $0.15 during midday trading on Wednesday, reaching $83.75. 574 shares of the company’s stock were exchanged, compared to its average volume of 401,879. LivaNova has a 52-week low of $41.07 and a 52-week high of $90.25. The stock has a market capitalization of $4.11 billion, a PE ratio of -10.73 and a beta of 0.90. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.97 and a current ratio of 1.15. The business’s fifty day moving average price is $82.23 and its two-hundred day moving average price is $81.35.
In related news, Director Daniel Jeffrey Moore sold 1,000 shares of the business’s stock in a transaction dated Wednesday, September 1st. The stock was sold at an average price of $82.40, for a total value of $82,400.00. Following the completion of the sale, the director now directly owns 31,630 shares of the company’s stock, valued at $2,606,312. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 0.37% of the stock is owned by insiders.
An institutional investor recently raised its position in LivaNova stock. Morgan Stanley lifted its holdings in shares of LivaNova PLC (NASDAQ:LIVN) by 0.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 53,468 shares of the company’s stock after buying an additional 428 shares during the period. Morgan Stanley owned approximately 0.11% of LivaNova worth $4,497,000 at the end of the most recent reporting period. 94.97% of the stock is currently owned by institutional investors.
LivaNova Company Profile
LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. It operates through the Cardiovascular and Neuromodulation segments. The Cardiovascular segment develops, produces, and sells cardiopulmonary products, heart valves, and circulatory support products.
Further Reading: What Factors Can Affect Return on Equity?
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.